David L. Lacey

David is the non-executive director of Inbiomotion. He received both his undergraduate and medical degrees from the University of Colorado where his work was recognized with a nomination to Phi Beta Kappa and Alpha Omega Alpha, respectively. He continued his training at Washington University, St. Louis, Missouri, pursuing research in bone biology and completing his postgraduate medical education. He moved from academia to industry when he joined Amgen, during the last five years of his tenure he served as head of discovery research (> 1200 FTEs).

In this capacity, he charted the course and motivated a diverse senior team of scientific leaders from different disciplines as well as engaging and managing a diverse stakeholder network. At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders and neuroscience.

David’s work and Amgen’s pipeline excellence was recognized by Scrip (November 2009) and R&D Directions (January 2011). Scientifically, he has played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen, which led to the development of the anti-RANKL human mAb denosumab; an emerging dual blockbuster for both osteoporosis and cancer-related bone diseases. Denosumab has received a number of awards including the US 2011 Prix Galien for best new biotechnology product and the 2010 Scrip award for best new drug. Following his semi-retirement, he has continued to be active in the biopharmaceutical industry.

His current activities include advising academic institutions, biotechnology companies, and venture capital firms.